References

1. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA (2012) Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 367: 1891-1900. View
2. Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, et al. (2012) Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 380: 29-36. View
3. Iso H (2011) Lifestyle and cardiovascular disease in Japan. J Atheroscler Thromb 18: 83-88. View
4. Heart Care Network Groups (2009) Current trends in lifestyle-related disease management by general practitioners: a report from the "Heart Care Network" groups. J Atheroscler Thromb 16: 799-806. View
5. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. (2011) ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. Eur Heart J 32: 1769. View
6. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, et al. (2014) American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 129: S1. View
7. Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, et al. (2013) Japan Atherosclerosis Society. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb 20: 517. View
8. Kurihara Y (2007) A large-scale, prospective post-marketing surveillance of pitavastatin (LIVALO®tablet) Drug use investigation. Jpn Pharmacol Ther 35: 9-40. View
9. Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, et al. (2010) Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 209: 189-194. View
10. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, et al.; GAUSS-2 Investigators (2014) Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol 63: 2541-2548. View
11. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, et al.; TESLA Investigators (2015) Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, doubleblind, placebo-controlled trial. Lancet. 385: 341-350. View
12. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, et al.; LAPLACE-2 Investigators (2014) Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 311: 1870-1182. View
13. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, et al.; DESCARTES Investigators (2014) A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. New Engl J Med 370: 1809-1819. View
14. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, et al. (2012) Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 59: 2344-2353. View
15. Konishi H, Miyauchi K, Kasai T, Tsuboi S, Ogita M, et al. (2015) Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention. Am J Cardiol. 115: 157-160. View
16. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, et al. (2015) Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1500. View
17. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, et al. (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372: 1489-1499. View
18. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, et al. (2015) Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Metaanalysis. Ann Intern Med 163: 40-51. View